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ABSTRACT 28 
A pan-susceptible Salmonella enterica serovar Worthington was detected in the stools of a man 29 
returning from Sri Lanka. Under ceftriaxone treatment, a third-generation cephalosporin 30 
(3GCs)-resistant Salmonella Worthington was isolated after 8 days. Molecular analyses 31 
indicated that the two isolates were identical. However, the latter strain acquired a blaDHA-1-32 
carrying IncFII plasmid probably from a Citrobacter amalonaticus colonizing the gut. This is 33 
the first report of in vivo acquisition of plasmid-mediated resistance to 3GCs in Salmonella 34 
enterica.            35 
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Salmonella enterica are important pathogens responsible for gastroenteritis, but may also cause 36 
invasive infections where third-generation cephalosporins (3GC) and fluoroquinolones are the 37 
treatments of choice (1). However, the rapid emergence of 3GC-resistant (3GC-R) strains in 38 
both human and non-human settings is representing a public health concern (2, 3). Most of these 39 
isolates produce extended-spectrum β-lactamases (ESBLs) or the plasmid-mediated AmpC 40 
(pAmpC) CMY-2 (4-7), while the DHA-1 pAmpC is rarely reported (8-12).  41 
In this scenario, we note that cases of infection due to Salmonella enterica where the organism 42 
undergoes in vivo acquisition of blaESBL or blapAmpC via mobile genetic elements (MGEs) from 43 
other species have not yet been reported. Here, we describe a clinical case in which this 44 
phenomenon was observed and define the characteristics of the recovered isolates. 45 
On November 2018, a 77-year old man presented with fever and respiratory symptoms five 46 
days after returning from a two-month trip to Sri Lanka. His personal history included an IgG4 47 
cholangiopathy requiring immunosuppressive drugs and hepatocellular carcinoma. Ceftriaxone 48 
was started empirically after sampling. Blood, sputum and urine cultures did not revealed 49 
bacterial growth. PCR from a nasopharyngeal swab detected Influenza B. Antimicrobial 50 
treatment was stopped after 6 days and the patient discharged. Two days prior to discharge, he 51 
passed loose stools revealing a pan-susceptible Salmonella spp. (strain 7101.67) in culture.  52 
Five days after discharge, the patient was readmitted because of fatigue, nausea, persistent 53 
respiratory symptoms and intermittent diarrhea. Another Salmonella spp. (strain 7102.58) grew 54 
in stools culture. Ceftriaxone was restarted, but upon detection of resistance towards 3GCs 55 
switched to meropenem for 3 days, and then streamlined to cefepime for 10 days (Text S1 and 56 
Figure S1: full description of the clinical case). 57 
In the routine clinical laboratory, stools were enriched in Selenite broth and then plated on 58 
XLD, MacConkey II, Rambach, and Brilliant Green agar plates (Oxoid). Bacterial identification 59 
(ID) was achieved at genus level using the MALDI-TOF MS (Bruker). Species, subspecies and 60 
serovar were determined using the White-Kauffmann-Le Minor scheme (13). Antimicrobial 61 
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susceptibility tests (ASTs) were performed using the disk-diffusion method for all 62 
morphologically different colonies  (14). Production of ESBL(s) was further investigated using 63 
the double-disk synergy test (DDST) (15), while MICs were obtained implementing both 64 
GNX2F and ESB1F Sensititre microdilution panels (ThermoFisher Scientific) and interpreted 65 
according to the EUCAST criteria (16).  66 
Based on the MIC values, Salmonella 7101.67 was confirmed as pan-susceptible, whereas 67 
isolate 7102.58 was resistant to azithromycin, β-lactam/β-lactamase inhibitor combinations and 68 
3GCs, but not to cefepime (Table 1). For 7102.58, DDST results were also suspicious for the 69 
production of an inducible AmpC (Figure S2) (11). Both isolates were identified as Salmonella 70 
enterica subsp. enterica Worthington (13). In Western countries, this serovar is rarely detected 71 
in human and non-human settings (4, 5, 17). Specific data regarding Sri Lanka are scarce (18), 72 
but we emphasize that Salmonella Worthington has a high prevalence in India where it is 73 
responsible for outbreaks in both hospital and community settings (19-21). 74 
Presence of ESBL, pAmpC, and carbapenemase bla genes was rapidly investigated using 75 
the CT103XL microarray (Check-Points) indicating that Salmonella 7101.67 did not possess bla 76 
genes, whereas 7102.58 carried the blaDHA-1 (22). Moreover, analysis of clonality using the rep-77 
PCR showed that the two strains had identical band patterns (Figure S3) (23, 24). These findings 78 
supported the hypothesis that the first isolate acquired a MGE harboring the blaDHA-1. Therefore, 79 
to confirm such hypothesis conjugation experiments were performed at 37°C using the 80 
Escherichia coli J53 recipient (rifampicin-resistant) and selecting on MacConkey plates 81 
containing ampicillin and rifampicin (both 50 µg/ml) (25). As a result, transconjugants 82 
possessing blaDHA-1 were obtained at a frequency of 5.2 x 10
-6
 (Table 1). 83 
Several ESBL- or CMY-2-producing Salmonella Worthington strains have been isolated from 84 
humans (India) and food animals (United States) (4, 26), but those expressing the DHA-1 were 85 
not yet detected. To date, this inducible pAmpC was exceptionally reported only in Salmonella 86 
serovars Thompson, Enteritidis, Indiana, and Anatum (9, 10, 12, 27, 28). 87 
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For both Salmonella isolates whole-genome sequencing (WGS) was performed using both 88 
NovaSeq 6000 (Illumina) and MinION (Oxford Nanopore) (6, 25). Annotation was achieved 89 
using the NCBI Prokaryotic Genome Annotation Pipeline. Genomes were analyzed employing 90 
the tools of the Center for Genomic Epidemiology (www.genomicepidemiology.org/). Results 91 
indicated that isolate 7101.67 carried aac(6’)-Ia in the chromosome and qnrB19 on a 2.5kb 92 
Col440I plasmid; four additional plasmids (not typable) without antimicrobial resistance genes 93 
(ARGs) were also present. Conversely, Salmonella 7102.58 possessed an additional 82kb IncFII 94 
plasmid (named p7102_58-6) harboring qnrB4, sul1, dfrA17, mph(A), and blaDHA-1 ARGs 95 
(GenBank: CP039513). Both Salmonella strains were of ST592 and genetically identical as 96 
confirmed by cgMLST analysis (cgST 161578; Figure S4). 97 
Worldwide, blaDHA-1 is mostly detected in Klebsiella pneumoniae and E. coli and it is harbored 98 
by plasmids of different size and incompatibility group (8, 29). In Switzerland, blaDHA-1 has 99 
been associated to plasmids R, FIIk, F, and HIB (30-32). To our knowledge, only two IncFII 100 
plasmids carrying blaDHA-1 were previously reported: one (82kb) in E. coli from UK (GenBank: 101 
MK048477) and almost identical to p7102_58-6, while another one (111kb) in ST11 K. 102 
pneumoniae from Malaysia (GenBank: KY751925) (33). In all of these IncFII plasmids, the 103 
blaDHA-1 [along with qnrB4, sul1, and mph(A)] was part of a common large module (16.5kb) 104 
very similar to others already deposited and carried by different Inc group plasmids (Figure 1). 105 
Such element is included between two IS26, comprises a phage shock protein operon, and has 106 
been likely acquired through a transposition process (7). 107 
In the effort to detect the natural blaDHA-1 donor carried at gut level, stools (~100 µg) were 108 
enriched overnight in Luria-Bertani broth supplemented with cefoxitin (12 µg/ml) and 109 
vancomycin (1.5 µg/ml). One-hundred µl were plated on ChromID ESBL (bioMérieux) and 110 
incubated overnight. Thirty resistant colonies underwent PCR to detect blaDHA (34); those 111 
resulting positive were characterized (ID, AST, and WGS) as described above. 112 
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Unfortunately, patient’s stools collected during the hospitalizations (November/December, 113 
2018) were not available for further analyses. Only on April 2019 we could analyze such sample 114 
and a blaDHA-1-positive Citrobacter amalonaticus (strain #4) was detected (Figure S5, Table 1). 115 
No further blaDHA-1-positive species (e.g., E. coli or Klebsiella spp.) were found, with the 116 
exception of the blaDHA-1-positive Salmonella Worthington that was still isolated implementing 117 
routine culture methods. WGS analysis indicated that C. amalonaticus #4 did not harbor ARGs 118 
in the chromosome, while the blaDHA-1 was carried on an 82kb IncFII plasmid identical to 119 
p7102_58-6 (Figure 1).    120 
To our knowledge, this is the first report of in vivo acquisition of plasmid-mediated 121 
resistance to 3GCs in a clinical isolate of Salmonella enterica. Our best hypothesis is that, under 122 
ceftriaxone selective pressure, the initial pan-susceptible Salmonella strain acquired via 123 
conjugation the blaDHA-1-IncFII plasmid. This MGE was carried by the C. amalonaticus 124 
colonizing the intestinal tract and likely acquired in Sri Lanka together with the initial 125 
Salmonella Worthington. Our finding also emphasize that traveling to the Indian sub-continent 126 
represents a serious risk to import unusual multidrug-resistant Gram-negatives that may serve as 127 
a source of life-threatening resistance genes that can be transferred to important human 128 
pathogens.    129 
 130 
Accession numbers. Salmonella Worthington 7101.67 (GenBank: CP039503-CP039508), 131 
Salmonella Worthington 7102.58 (GenBank: CP039509-CP039515), and Citrobacter 132 
amalonaticus #4 (GenBank: CP041362-CP041363).  133 
 on July 30, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
7 
 
ACKNOWLEDGEMENTS 134 
This work was supported by the NRP-72, “National Research Programme, Antimicrobial 135 
Resistance” (Swiss National Science Foundation; grant No. 177378 to AE). Partial support was 136 
also provided by NRP-72 grant No. 177368 to PMK.  137 
We thank Dr. Maria V. Elzi,
 
Dr. Carlo Casanova, Mr. Thomas Büdel (Institute for Infectious 138 
Diseases, University of Bern) and Dr. Stefanie Springe (Praxis im Monbijou, Bern) for the 139 
support.  140 
 on July 30, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
8 
 
REFERENCES 141 
1. Crump JA, Sjolund-Karlsson M, Gordon MA, Parry CM. 2015. Epidemiology, Clinical 142 
Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial 143 
Management of Invasive Salmonella Infections. Clin Microbiol Rev 28:901-937. 144 
2. European Food Safety Authority (EFSA) and European Centre for Disease Prevention 145 
and Control (ECDC). 2019. The European Union summary report on antimicrobial 146 
resistance in zoonotic and indicator bacteria from humans, animals and food in 2017. EFSA 147 
Journal 17:5598-5876. 148 
3. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the 149 
United States, 2013. Available online: https://www.cdc.gov/drugresistance/pdf/ar-threats-150 
2013-508.pdf. 151 
4. Elnekave E, Hong SL, Lim S, Hayer SS, Boxrud D, Taylor AJ, Lappi V, Noyes N, 152 
Johnson TJ, Rovira A, Davies P, Perez A, Alvarez J. 2019. Circulation of Plasmids 153 
Harboring Resistance Genes to Quinolones and/or Extended-Spectrum Cephalosporins in 154 
Multiple Salmonella enterica Serotypes from Swine in the United States. Antimicrob 155 
Agents Chemother 63. 156 
5. Gonzalez-Sanz R, Herrera-Leon S, de la Fuente M, Arroyo M, Echeita MA. 2009. 157 
Emergence of extended-spectrum -lactamases and AmpC-type -lactamases in human 158 
Salmonella isolated in Spain from 2001 to 2005. J Antimicrob Chemother 64:1181-1186. 159 
6. Clement M, Ramette A, Bernasconi OJ, Principe L, Luzzaro F, Endimiani A. 2018. 160 
Whole-Genome Sequence of the First Extended-Spectrum -Lactamase-Producing Strain of 161 
Salmonella enterica subsp. enterica Serovar Napoli. Microbiology resource announcements 162 
7:e00973-18. 163 
7. Carattoli A. 2003. Plasmid-mediated antimicrobial resistance in Salmonella enterica. Curr 164 
Issues Mol Biol 5:113-122. 165 
8. Hennequin C, Ravet V, Robin F. 2018. Plasmids carrying DHA-1 -lactamases. European 166 
journal of clinical microbiology & infectious diseases 37:1197-1209. 167 
9. Yu F, Chen C, Chen Q, Yu X, Ding B, Yang L, Li Q, Qin Z, Parsons C, Zhang X, 168 
Zhang L, Qu D, Wang L, Pan J. 2012. Identification of transferable DHA-1 type AmpC 169 
-lactamases and two mutations in quinolone resistance-determining regions of Salmonella 170 
enterica serovar Thompson. J Med Microbiol 61:460-462. 171 
10. Rayamajhi N, Jung BY, Cha SB, Shin MK, Kim A, Kang MS, Lee KM, Yoo HS. 2010. 172 
Antibiotic resistance patterns and detection of blaDHA-1 in Salmonella species isolates from 173 
chicken farms in South Korea. Appl Environ Microbiol 76:4760-4764. 174 
11. Meini S, Tascini C, Cei M, Sozio E, Rossolini GM. 2019. AmpC -lactamase-producing 175 
Enterobacterales: what a clinician should know. Infection 47:363-375. 176 
12. Verdet C, Arlet G, Barnaud G, Lagrange PH, Philippon A. 2000. A novel integron in 177 
Salmonella enterica serovar Enteritidis, carrying the blaDHA-1 gene and its regulator gene 178 
ampR, originated from Morganella morganii. Antimicrob Agents Chemother 44:222-225. 179 
 on July 30, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
9 
 
13. Grimont PAD, Weill FX. WHO Collaborating Centre for Reference and Research on 180 
Salmonella. Antigenic formulae of the Salmonella serovars. 9th edition, 2007. 181 
14. Clinical Laboratory Standards Institute (CLSI). 2018. Performances Standards for 182 
Antimicrobial Susceptibility Testing; M100-S28. Wayne, PA, USA  183 
15. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2017. 184 
EUCAST guidelines for detection of resistance mechanisms and specific resistances of 185 
clinical and/or epidemiological importance. Version 2.0. 186 
16. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2019. 187 
Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0  188 
17. European Centre for Disease Prevention and Control (ECDC). 2014. Annual 189 
epidemiological report 2014 – food- and waterborne diseases and zoonoses. Stockholm: 190 
ECDC  191 
18. Tay MYF, Pathirage S, Chandrasekaran L, Wickramasuriya U, Sadeepanie N, 192 
Waidyarathna KDK, Liyanage LDC, Seow KLG, Hendriksen RS, Takeuchi MT, 193 
Schlundt J. 2019. Whole Genome Sequencing Analysis of Nontyphoidal Salmonella 194 
enterica of Chicken Meat and Human Origin Under Surveillance in Sri Lanka. Foodborne 195 
Pathog Dis 16:531-537. 196 
19. Kumar Y, Sharma A, Sehgal R, Kumar S. 2009. Distribution trends of Salmonella 197 
serovars in India (2001-2005). Trans R Soc Trop Med Hyg 103:390-394. 198 
20. Muley VA, Pol SS, Dohe VB, Nagdawane RP, Arjunwadkar VP, Pandit DP, 199 
Bharadwaj RS. 2004. Neonatal outbreak of Salmonella worthington in a general hospital. 200 
Indian J Med Microbiol 22:51-53. 201 
21. Sinha S, Pazhani GP, Sen B, Niyogi SK. 2006. Molecular Characterization of Salmonella 202 
enterica serotype Worthington isolated from childhood diarrhea cases in Kolkata, India. Jpn 203 
J Infect Dis 59:275-276. 204 
22. Bernasconi OJ, Principe L, Tinguely R, Karczmarek A, Perreten V, Luzzaro F, 205 
Endimiani A. 2017. Evaluation of a New Commercial Microarray Platform for the 206 
Simultaneous Detection of -Lactamase and mcr-1 and mcr-2 Genes in Enterobacteriaceae. 207 
J Clin Microbiol 55:3138-3141. 208 
23. Seiffert SN, Hilty M, Kronenberg A, Droz S, Perreten V, Endimiani A. 2013. 209 
Extended-spectrum cephalosporin-resistant Escherichia coli in community, specialized 210 
outpatient clinic and hospital settings in Switzerland. Journal of Antimicrobial 211 
Chemotherapy 68:2249-2254. 212 
24. Pires J, Kuenzli E, Kasraian S, Tinguely R, Furrer H, Hilty M, Hatz C, Endimiani A. 213 
2016. Polyclonal Intestinal Colonization with Extended-Spectrum Cephalosporin-Resistant 214 
Enterobacteriaceae upon Traveling to India. Frontiers in Microbiology 7. 215 
25. Luzzaro F, Clement M, Principe L, Viaggi V, Bernasconi OJ, Endimiani A. 2019. 216 
Characterization of the first ESBL-producing Shigella sonnei Clinical Isolate in Italy. 217 
Journal of global antimicrobial resistance 17:58-59. 218 
26. Jain P, Roy S, Viswanathan R, Basu S, Singh AK, Dutta S. 2013. Concurrent and 219 
transferable resistance to extended-spectrum cephalosporins, monobactam and 220 
 on July 30, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
10 
 
fluoroquinolone in a Salmonella enterica serovar Worthington blood isolate from a neonate 221 
in Kolkata, India. Int J Antimicrob Agents 41:494-495. 222 
27. Gaillot O, Clement C, Simonet M, Philippon A. 1997. Novel transferable -lactam 223 
resistance with cephalosporinase characteristics in Salmonella enteritidis. J Antimicrob 224 
Chemother 39:85-87. 225 
28. Chiou CS, Hong YP, Liao YS, Wang YW, Tu YH, Chen BH, Chen YS. 2019. New 226 
Multidrug-Resistant Salmonella enterica Serovar Anatum Clone, Taiwan, 2015-2017. 227 
Emerg Infect Dis 25:144-147. 228 
29. Hennequin C, Chlilek A, Beyrouthy R, Bonnet R, Robin F. 2018. Diversity of DHA-1-229 
encoding plasmids in Klebsiella pneumoniae isolates from 16 French hospitals. J 230 
Antimicrob Chemother 73:2981-2989. 231 
30. Schluter A, Nordmann P, Bonnin RA, Millemann Y, Eikmeyer FG, Wibberg D, 232 
Puhler A, Poirel L. 2014. IncH-type plasmid harboring blaCTX-M-15, blaDHA-1, and qnrB4 233 
genes recovered from animal isolates. Antimicrob Agents Chemother 58:3768-3773. 234 
31. Wohlwend N, Endimiani A, Francey T, Perreten V. 2015. Third-Generation-235 
Cephalosporin-Resistant Klebsiella pneumoniae Isolates from Humans and Companion 236 
Animals in Switzerland: Spread of a DHA-Producing Sequence Type 11 Clone in a 237 
Veterinary Setting. Antimicrob Agents Chemother 59:2949-2955. 238 
32. Pilo P, Vogt D, Origgi FC, Endimiani A, Peterson S, Perreten V. 2015. First report of a 239 
multidrug-resistant Klebsiella pneumoniae of sequence type 11 causing sepsis in a free-240 
ranging beaver (Castor fiber). Environmental Microbiology Reports 7:351-353. 241 
33. Kim SY, Ko KS. 2019. Diverse Plasmids Harboring blaCTX-M-15 in Klebsiella pneumoniae 242 
ST11 Isolates from Several Asian Countries. Microb Drug Resist 25:227-232. 243 
34. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. 2010. Development of a set of 244 
multiplex PCR assays for the detection of genes encoding important beta-lactamases in 245 
Enterobacteriaceae. J Antimicrob Chemother 65:490-495. 246 
 247 
  248 
 on July 30, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
11 
 
Table 1. Antimicrobial susceptibility tests (ASTs) for the Salmonella, E. coli J53 transconjugant, and C. amalonaticus 249 
strains   250 
Antibiotics 
MIC, µg/ml 
Salmonella 
Worthington 
7101.67 
Salmonella 
Worthington 
7102.58 
(collected 8 days later) 
E. coli J53 
E. coli J53 
Transconjugant 
(donor 7102.58) 
Citrobacter 
amalonaticus #4
 c
 
Ampicillin ≤4, S ≥32, R ≤4, S ≥32, R ≥32, R 
Piperacillin-tazobactam ≤2, S 64, R ≤2, S ≤2, S 8, S 
Ticarcillin-clavulanate ≤8, S ≥256, R ≤8, S 128, R ≥256, R 
Cephalotin ≤4, NA ≥32, NA ≤4, NA ≥32, NA ≥32, NA 
Cefoxitin ≤2, NA ≥128, NA ≤2, NA ≥128, NA ≥128, NA 
Ceftriaxone ≤0.5, S 32, R ≤0.5, S 2, I 8, R 
Cefotaxime ≤0.125, S ≥128, R ≤0.125, S 16, R 32, R 
Cefotaxime/clavulanate ≤0.0625, NA ≥128, NA ≤0.0625, NA 8, NA 64, NA 
Ceftazidime ≤0.125, NA ≥256, R ≤0.125, S 32, R 128, R 
Cefotaxime/clavulanate 0.25, NA ≥256, NA ≤0.0625, NA 16, NA ≥256, NA 
Cefepime ≤0.5, S  ≤0.5, S ≤0.5, S  ≤0.5, S ≤0.5, S 
Aztreonam ≤1, S ≥32, R ≤1, S 4, R 16, R 
Imipenem ≤0.25, S ≤0.25, S ≤0.25, S ≤0.25, S ≤0.25, S 
Meropenem ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S 
Doripenem ≤0.0625, S ≤0.0625, S ≤0.0625, S ≤0.0625, S ≤0.0625, S 
Ertapenem ≤0.125, S ≤0.125, S ≤0.125, S ≤0.125, S ≤0.125, S 
Gentamicin ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S 
Tobramycin ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S 4, I 
Amikacin ≤2, S ≤2, S ≤2, S ≤2, S ≤2, S 
Ciprofloxacin ≤0.125, NI 0.5, NI ≤0.125, S ≤0.125, S 1, R 
Levofloxacin ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S ≤0.5, S 
Azithromycin 
b
 8, NA ≥256, NA - - - 
Doxycycline ≤1, NA ≤1, NA ≤1, NA ≤1, NA 4, NA 
Minocycline ≤1, NA ≤1, NA ≤1, NA ≤1, NA 4, NA 
Tigecycline ≤0.125, NA ≤0.125, NA ≤0.125, S ≤0.125, S 1, R 
Cotrimoxazole ≤0.25, S 1, S ≤0.25, S ≤0.25, S ≥8, R 
Colistin ≤0.125, S ≤0.125, S ≤0.125, S ≤0.125, S ≤0.125, S 
Note. R, resistant; I, intermediate; S, susceptible; NI, not interpretable; NA, not available; -, not tested 251 
a
 MICs were obtained with microdilution Sensititre panels (GNX2F and ESB1F) and interpreted according to the EUCAST 2019 252 
criteria (16) 253 
b
 The azithromycin MIC value was obtained implementing the Etest (bioMérieux) method. The EUCAST 2019 does not provide 254 
interpretative criteria, but strains with MIC≤16 µg/ml are defined as wild-type (16) 255 
c
 MICs for six C. amalonaticus strains were available (see Figure S5). Since all of them had the same phenotype, here we show only 256 
strain #4 as representative (this strain also underwent WGS) 257 
 on July 30, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
12 
 
LEGEND TO THE FIGURE 1 258 
 259 
Figure 1. Map of the IncFII-DHA-1 plasmid carried by Salmonella Worthington 7102.58. From 260 
the center to outer part: GC skew, GC content, BLAST hits from plasmid containing the same 261 
region and annotated codons. For each plasmid, species, host, region, and year of isolation along 262 
with Inc group are indicated. Ca, Citrobacter amalonaticus; Ec, E. coli; Kp, K. pneumoniae; Kv, 263 
K. variicola; Cs, Cronobacter sakazakii; SL, Salmonella Lamita; SA, Salmonella Anatum; NA, 264 
not available. Image was created using BRIG software with blast option “-culling_limit 1”.  265 
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Ec, Human, UK, NA, IncFII 
Ec, Soil, China, 2014, IncF/FII 
Kp, NA, Malaysia, 2008, IncFII 
Kp, Human, France, 2008, IncR 
Kp, Human, France, 2012-13, IncR 
Kp, Human, France, 2012-13, IncR 
Kp, Human, France, 2012-13, IncR 
Cs, Human, China, 2015, IncHI2 
SL, Human, China, NA, IncHI2 
Kv, Human, France, 2012-13, IncL/M 
GenBank Legend 
SA, Human, Taiwan, 2013, IncN3 
CP041363 
p7102_58-6 
22806-23510 
7050-7754 
12913-14052 
4445-5149 
Ca, Human, Switzerland, 2019, IncFII 
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